Uncategorized
Amati backs COVID-19 clinical trial with investment in Synairgen
With the Coronavirus pandemic accelerating, Amati AIM VCT has announced that two of its portfolio holdings, Byotrol plc and Tristel plc, which both produce disinfectant products, have entered a know-how licence and commercial collaboration. Dr Paul Jourdan, Founder and CEO of Amati Global Investors says he is “delighted to see…
Continue Reading
Subscribe to unlock the full article and access premium financial content.